BEAM
Price
$27.89
Change
+$0.02 (+0.07%)
Updated
Feb 3 closing price
Capitalization
2.83B
27 days until earnings call
Intraday BUY SELL Signals
IDYA
Price
$34.23
Change
+$7.44 (+27.77%)
Updated
Feb 3 closing price
Capitalization
3B
55 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

BEAM vs IDYA

Header iconBEAM vs IDYA Comparison
Open Charts BEAM vs IDYABanner chart's image
Beam Therapeutics
Price$27.89
Change+$0.02 (+0.07%)
Volume$1.21M
Capitalization2.83B
IDEAYA Biosciences
Price$34.23
Change+$7.44 (+27.77%)
Volume$639.01K
Capitalization3B
BEAM vs IDYA Comparison Chart in %
View a ticker or compare two or three
VS
BEAM vs. IDYA commentary
Feb 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BEAM is a Hold and IDYA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Feb 04, 2026
Stock price -- (BEAM: $27.89 vs. IDYA: $34.23)
Brand notoriety: BEAM and IDYA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BEAM: 66% vs. IDYA: 69%
Market capitalization -- BEAM: $2.83B vs. IDYA: $3B
BEAM [@Biotechnology] is valued at $2.83B. IDYA’s [@Biotechnology] market capitalization is $3B. The market cap for tickers in the [@Biotechnology] industry ranges from $118.13B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BEAM’s FA Score shows that 0 FA rating(s) are green whileIDYA’s FA Score has 1 green FA rating(s).

  • BEAM’s FA Score: 0 green, 5 red.
  • IDYA’s FA Score: 1 green, 4 red.
According to our system of comparison, IDYA is a better buy in the long-term than BEAM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BEAM’s TA Score shows that 3 TA indicator(s) are bullish while IDYA’s TA Score has 3 bullish TA indicator(s).

  • BEAM’s TA Score: 3 bullish, 6 bearish.
  • IDYA’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, both BEAM and IDYA are a bad buy in the short-term.

Price Growth

BEAM (@Biotechnology) experienced а -9.15% price change this week, while IDYA (@Biotechnology) price change was -1.47% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -4.22%. For the same industry, the average monthly price growth was +3.03%, and the average quarterly price growth was +35.17%.

Reported Earning Dates

BEAM is expected to report earnings on Mar 03, 2026.

IDYA is expected to report earnings on Mar 31, 2026.

Industries' Descriptions

@Biotechnology (-4.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IDYA($3B) has a higher market cap than BEAM($2.83B). BEAM YTD gains are higher at: 0.613 vs. IDYA (-0.984). IDYA has higher annual earnings (EBITDA): -204.84M vs. BEAM (-434.55M). BEAM has more cash in the bank: 1.08B vs. IDYA (787M). IDYA has less debt than BEAM: IDYA (27.2M) vs BEAM (151M). IDYA has higher revenues than BEAM: IDYA (215M) vs BEAM (55.7M).
BEAMIDYABEAM / IDYA
Capitalization2.83B3B94%
EBITDA-434.55M-204.84M212%
Gain YTD0.613-0.984-62%
P/E RatioN/AN/A-
Revenue55.7M215M26%
Total Cash1.08B787M137%
Total Debt151M27.2M555%
FUNDAMENTALS RATINGS
BEAM vs IDYA: Fundamental Ratings
BEAM
IDYA
OUTLOOK RATING
1..100
7467
VALUATION
overvalued / fair valued / undervalued
1..100
35
Fair valued
28
Undervalued
PROFIT vs RISK RATING
1..100
10063
SMR RATING
1..100
9794
PRICE GROWTH RATING
1..100
4445
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5075

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IDYA's Valuation (28) in the null industry is in the same range as BEAM (35). This means that IDYA’s stock grew similarly to BEAM’s over the last 12 months.

IDYA's Profit vs Risk Rating (63) in the null industry is somewhat better than the same rating for BEAM (100). This means that IDYA’s stock grew somewhat faster than BEAM’s over the last 12 months.

IDYA's SMR Rating (94) in the null industry is in the same range as BEAM (97). This means that IDYA’s stock grew similarly to BEAM’s over the last 12 months.

BEAM's Price Growth Rating (44) in the null industry is in the same range as IDYA (45). This means that BEAM’s stock grew similarly to IDYA’s over the last 12 months.

BEAM's P/E Growth Rating (100) in the null industry is in the same range as IDYA (100). This means that BEAM’s stock grew similarly to IDYA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BEAMIDYA
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
64%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
72%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
78%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
69%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
77%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
77%
Bearish Trend 1 day ago
84%
Advances
ODDS (%)
Bullish Trend 14 days ago
76%
Bullish Trend 1 day ago
77%
Declines
ODDS (%)
Bearish Trend 8 days ago
83%
Bearish Trend 6 days ago
75%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
79%
Bullish Trend 1 day ago
76%
Aroon
ODDS (%)
Bullish Trend 1 day ago
76%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
BEAM
Daily Signal:
Gain/Loss:
IDYA
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HFYCX14.600.16
+1.11%
Hartford Schroders Intl Multi-Cp Val C
VMMSX31.080.24
+0.78%
Vanguard Emerg Mkts Sel Stk Inv
BCREX14.990.07
+0.47%
BlackRock Real Estate Securities Inv C
OAYMX171.31-1.50
-0.87%
Oakmark Advisor
ETCEX12.97-0.32
-2.41%
Eventide Exponential Technologies C

BEAM and

Correlation & Price change

A.I.dvisor indicates that over the last year, BEAM has been closely correlated with CRSP. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is a high statistical probability that if BEAM jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BEAM
1D Price
Change %
BEAM100%
-0.11%
CRSP - BEAM
66%
Closely correlated
+1.34%
RXRX - BEAM
62%
Loosely correlated
-1.91%
NTLA - BEAM
62%
Loosely correlated
-0.08%
PRME - BEAM
61%
Loosely correlated
+0.26%
VIR - BEAM
58%
Loosely correlated
-0.39%
More

IDYA and

Correlation & Price change

A.I.dvisor indicates that over the last year, IDYA has been loosely correlated with NUVL. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if IDYA jumps, then NUVL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IDYA
1D Price
Change %
IDYA100%
+0.50%
NUVL - IDYA
59%
Loosely correlated
+2.12%
OCUL - IDYA
57%
Loosely correlated
-6.99%
XENE - IDYA
56%
Loosely correlated
+1.62%
XNCR - IDYA
55%
Loosely correlated
-0.99%
BEAM - IDYA
54%
Loosely correlated
-0.11%
More